Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)

SHA:603229 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	800.79	795.07	814.85	764.23	568.89	405.1
Other Revenue	0.22	0.22	1.92	0.32	0.81	4.15
Revenue	801.01	795.29	816.77	764.55	569.7	409.25
Revenue Growth (YoY)	-6.33%	-2.63%	6.83%	34.20%	39.21%	32.91%
Cost of Revenue	367.42	373.39	372.41	372.58	261.29	182.58
Gross Profit	433.59	421.9	444.36	391.96	308.41	226.67
Selling, General & Admin	124.95	123.21	118.41	114.55	81.25	63.71
Research & Development	105.47	100.42	78.06	67.07	68.82	50.77
Other Operating Expenses	10.54	6.54	3.32	1.97	4.64	4.05
Operating Expenses	248.32	236.19	199.81	186.76	156.21	117.78
Operating Income	185.27	185.71	244.54	205.2	152.2	108.89
Interest Expense	-7.76	-7.76	-7.99	-6.11	-1.47	-1.38
Interest & Investment Income	48.91	43.08	35.75	9.6	5.78	8.23
Currency Exchange Gain (Loss)	11.4	11.4	11.37	40.58	-9.67	-21.72
Other Non Operating Income (Expenses)	-3.35	-1.5	-0.6	-0.44	-0.44	-0.39
EBT Excluding Unusual Items	234.46	230.92	283.07	248.84	146.41	93.63
Gain (Loss) on Sale of Investments	6.31	5.5	-4.49	4.95	11.66	-5.23
Gain (Loss) on Sale of Assets	-	-	-	-	-0.52	-0.52
Asset Writedown	-0.15	-0.15	-0.37	-1.58	-	-
Other Unusual Items	6.3	3.93	12.55	3.66	1.84	7.62
Pretax Income	246.92	240.2	290.76	255.86	159.39	95.5
Income Tax Expense	33.41	33.41	36.86	20.48	13.46	8.66
Net Income	213.51	206.79	253.9	235.38	145.93	86.84
Net Income to Common	213.51	206.79	253.9	235.38	145.93	86.84
Net Income Growth	-21.71%	-18.55%	7.87%	61.29%	68.05%	54.00%
Shares Outstanding (Basic)	839	827	819	804	794	745
Shares Outstanding (Diluted)	839	827	819	804	794	745
Shares Change (YoY)	3.45%	0.99%	1.92%	1.16%	6.67%	0.25%
EPS (Basic)	0.25	0.25	0.31	0.29	0.18	0.12
EPS (Diluted)	0.25	0.25	0.31	0.29	0.18	0.12
EPS Growth	-24.32%	-19.36%	5.84%	59.45%	57.55%	53.62%
Free Cash Flow	28.15	66.62	58.38	-151.35	-136.95	45.52
Free Cash Flow Per Share	0.03	0.08	0.07	-0.19	-0.17	0.06
Dividend Per Share	0.100	0.100	0.092	0.057	0.037	0.023
Dividend Growth	8.58%	8.58%	61.30%	53.91%	62.72%	39.88%
Gross Margin	54.13%	53.05%	54.40%	51.27%	54.14%	55.39%
Operating Margin	23.13%	23.35%	29.94%	26.84%	26.72%	26.61%
Profit Margin	26.66%	26.00%	31.09%	30.79%	25.61%	21.22%
Free Cash Flow Margin	3.51%	8.38%	7.15%	-19.80%	-24.04%	11.12%
EBITDA	253.29	248.24	285.14	239.68	182.22	134.32
EBITDA Margin	31.62%	31.21%	34.91%	31.35%	31.99%	32.82%
D&A For EBITDA	68.02	62.53	40.59	34.48	30.02	25.43
EBIT	185.27	185.71	244.54	205.2	152.2	108.89
EBIT Margin	23.13%	23.35%	29.94%	26.84%	26.71%	26.61%
Effective Tax Rate	13.53%	13.91%	12.68%	8.01%	8.45%	9.07%
Revenue as Reported	801.01	795.29	816.77	764.55	569.7	409.25

Source: S&P Global Market Intelligence. Standard template. Financial Sources.